Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
Open accessAbstract
OBJECTIVE: To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND METHODS: Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured. RESULTS: Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight. CONCLUSIONS: Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
After excluding the study of Forst et al., the pooled effect of three studies shows a statistical decline in MCP-1 level.
“after excluding the study of Forst et al., 79 the pooled effect of three studies 72,82 shows a statistical decline in MCP-1 level”
From The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 15 · Cited by 161
Research works printed but not linked: 13
- [1]Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S57– 63 18987271 PMC2585758
- [2]Diamant M Lamb HJ van de Ree MA Endert EL Groeneveld Y Bots ML Kostense PJ Radder JK. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 1495– 1501 15613416
- [3]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837– 853 9742976
- [4]Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773– 795 19336687 PMC2661582
- [6]Kim W Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470– 512 19074620 PMC2696340
- [7]Szayna M Doyle ME Betkey JA Holloway HW Spencer RG Greig NH Egan JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936– 1941 10830274
- [8]Li L Yang G Li Q Tan X Liu H Tang Y Boden G. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 2008; 10: 921– 930 18093209
- [9]Pérez-Tilve D González-Matías L Alvarez-Crespo M Leiras R Tovar S Diéguez C Mallo F. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007; 56: 143– 151 17192476
- [11]Horton ES Cohen A Gibson H Lamparello B Herzlinger S McFarland L. Effects of exenatide vs insulin glargine on cardiovascular risk factors in subjects with type 2 diabetes. Diabetologia 2009; 52: S298– S299
- [12]Jendle J Nauck MA Matthews DR Frid A Hermansen K Düring M Zdravkovic M Strauss BJ Garber AJ: LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163– 1172 19930006
- [13]Courrèges JP Vilsbøll T Zdravkovic M Le-Thi T Krarup T Schmitz O Verhoeven R Bugáñová I Madsbad S. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129– 1131 19183322 PMC2592347
- [14]Kim Chung le T Hosaka T Yoshida M Harada N Sakaue H Sakai T Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009; 390: 613– 618 19850014
- [15]Tushuizen ME Bunck MC Pouwels PJ van Waesberghe JH Diamant M Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015– 1017 16953843
- Authors
- Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Department of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden;
- Helsinki University Hospital (FI)
- Eli Lilly (Netherlands) (NL)
- Eli Lilly (United States) (US)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Bunck, Mathijs C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-04-27
- Volume
- 33
- Issue
- 8
- Pages
- 1734-1737
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2909051
- OpenAlex
- W2157869836
- Cited by
- 161
- References
- 15
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 5 · 2017: 8 · 2016: 6 · 2015: 13 · 2014: 14 · 2013: 14 · 2012: 18
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Eli Lilly and Company
- Amylin Pharmaceuticals
- Vrije Universiteit Amsterdam
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exenatide, type 2 diabetes, body composition, cardiovascular risk markers, insulin glargine, fat mass, adiponectin, C-reactive protein, endothelin-1, metformin, GLP-1 receptor agonists, weight loss, waist circumference
- MeSH terms
- Insulin Glargine, Exenatide, Body Composition, Body Weight, C-Reactive Protein, Cardiovascular Diseases, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Peptides, Risk Factors, Venoms, Absorptiometry, Photon, Endothelin-1, Insulin, Long-Acting, Adiponectin, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
